| Lung Non-Small Cell Carcinoma14 |
|---|
| ROS1 G2032R AND v::ROS1 Fusion | Lorlatinib | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID1251Preclinical study of PF-06463922 in NSCLC in-vitro, in-vivo and in enzyme assays. PF-06463922 showed inhibition of kinase activity, cell viability and tumor growth in wild-type, G2032R and L2026M muta… (full text at CIViC) PMID 25733882 · Zou et al., 2015 · Open in CIViC | civic |
| ROS1 G2032R AND v::ROS1 Fusion | Repotrectinib | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID12022In a phase 1-2 trial (NCT03093116), the ROS1/ALK/NTRK inhibitor repotrectinib demonstrated efficacy in NSCLC with ROS1 fusions. In the 56 patients who had previously received one ROS1 tyrosine kinase… (full text at CIViC) PMID 38197815 · Drilon et al., 2024 · Open in CIViC | civic |
| ROS1 G2032R AND v::ROS1 Fusion | Taletrectinib | Predictive | B | Supports Sensitivity Response | 2 | submitted | EID12236The TRUST-I study (NCT04395677) was a phase II, multicenter, single-arm, open-label trial conducted in China to evaluate taletrectinib for ROS1 fusion-positive, locally advanced, or metastatic non-sma… (full text at CIViC) PMID 38822758 · Li et al., 2024 · Open in CIViC | civic |
| v::ROS1 Fusion | Ceritinib | Predictive | B | Supports Sensitivity Response | 4 | submitted | EID11334In this phase II trial, 404 patients with advanced NSCLC underwent ROS1 pre-screening, and 32 patients with ROS1 rearrangement confirmed with FISH were enrolled. All patients except two were crizotini… (full text at CIViC) PMID 28520527 · Lim et al., 2017 · Open in CIViC | civic |
| v::ROS1 Fusion | Crizotinib | Predictive | A | Supports Sensitivity Response | 4 | accepted | EID688An expansion cohort of a phase-1 Crizotinib study found a 72% objective response rate among 50 patients with ROS1 rearrangement. The study did not compare to patients without rearrangement that were t… (full text at CIViC) PMID 25264305 · Shaw et al., 2014 · Open in CIViC | civic |
| v::ROS1 Fusion | Crizotinib | Predictive | A | Supports Sensitivity Response | 3 | accepted | EID1030In a retrospective study, 30 patients were evaluated after crizotinib treatment for stage IV NSCLC confirmed for ROS1 rearrangement. On crizotinib, 24 of the patients achieved objective responses incl… (full text at CIViC) PMID 25667280 · Mazières et al., 2015 · Open in CIViC | civic |
| v::ROS1 Fusion | Crizotinib | Predictive | A | Supports Sensitivity Response | 5 | accepted | EID7282In the ongoing phase 1 study PROFILE 1001, NSCLC patients with ROS1 rearrangement confirmed by FISH or RT-PCR received crizotinib 250mg twice daily. Among 53 patients, the ORR was 72% (95% CI, 58% to … (full text at CIViC) PMID 30980071 · Shaw et al., 2019 · Open in CIViC | civic |
| v::ROS1 Fusion | Crizotinib | Predictive | A | Supports Sensitivity Response | 4 | accepted | EID7933A phase 2 clinical trial studied the efficacy of Crizotinib in East Asian NSCLC patients positive for ROS1 rearrangements (detected by RT-PCR AmoyDx assay) and negative for ALK1 rearrangements. Of the… (full text at CIViC) PMID 29596029 · Wu et al., 2018 · Open in CIViC | civic |
| v::ROS1 Fusion | Crizotinib | Predictive | A | Supports Sensitivity Response | 3 | submitted | EID8916The phase 2 EUCROSS trial (NCT02183870) examined the safety and efficacy of 250mg crizotinib twice daily in European ROS1-rearranged NSCLC patients. ROS1 status was assessed by break-apart FISH or bot… (full text at CIViC) PMID 30978502 · Michels et al., 2019 · Open in CIViC | civic |
| v::ROS1 Fusion | Entrectinib | Predictive | A | Supports Sensitivity Response | 3 | accepted | EID2951Two phase I studies included 119 patients with advanced or metastatic solid tumors, which included 28 patients with ROS1 rearrangements (n=28) where the overall safety and antitumor activity of entrec… (full text at CIViC) PMID 28183697 · Drilon et al., 2017 · Open in CIViC | civic |
| v::ROS1 Fusion | Entrectinib | Predictive | A | Supports Sensitivity Response | 5 | accepted | EID11123Describes a meta-analysis of three separate phase I or II trials: ALKA-372-001, STARTRK-1, and STARTRK-2. All of these evaluate entrectinib in ROS-1 fusion-positive NSCLC (locally advanced or metastat… (full text at CIViC) PMID 31838015 · Drilon et al., 2020 · Open in CIViC | civic |
| v::ROS1 Fusion | Lorlatinib | Predictive | B | Supports Sensitivity Response | 4 | submitted | EID11335In this open-label, single-arm, phase 1-2 trial, 364 patients with histologically or cytologically confirmed advanced ROS1-positive NSCLC, with or without CNS metastases were assessed. Of them, 69 wit… (full text at CIViC) PMID 31669155 · Shaw et al., 2019 · Open in CIViC | civic |
| v::ROS1 Fusion | Repotrectinib | Predictive | A | Supports Sensitivity Response | 4 | submitted | EID12021In a phase 1-2 trial (NCT03093116), the ROS1/ALK/NTRK inhibitor repotrectinib demonstrated efficacy in NSCLC with ROS1 fusions. Among the 71 ROS1-inhibitor-naive patients, 56 (79%; 95% CI, 68 to 88) h… (full text at CIViC) PMID 38197815 · Drilon et al., 2024 · Open in CIViC | civic |
| v::ROS1 Fusion | Taletrectinib | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID12240The TRUST-I study (NCT04395677) was a phase II, multicenter, single-arm, open-label trial conducted in China to evaluate taletrectinib for ROS1 fusion-positive, locally advanced, or metastatic non-sma… (full text at CIViC) PMID 38822758 · Li et al., 2024 · Open in CIViC | civic |